Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anixa Biosciences (ANIX)
:ANIX
Holding ANIX?
Track your performance easily
ANIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.07 - $5.09
Previous CloseN/A
Volume56.82K
Average Volume (3M)109.18K
Market Cap
$83.07M
Enterprise Value$118.13M
Total Cash (Recent Filing)$6.84M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.03
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding32,196,860
10 Day Avg. Volume119,934
30 Day Avg. Volume109,176
Standard Deviation0.18
R-Squared0.07
Alpha0.00106
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)395.56
Price to Cash Flow (P/CF)-22.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue562.51
Enterprise Value/Gross Profit562.51
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$7.00Price Target Upside171.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Anixa Biosciences News
PremiumCompany Announcements
Anixa Biosciences Reports Promising Phase 1 Vaccine Results
Ownership Overview
5.21% Insiders
5.28% Mutual Funds
0.09% Other Institutional Investors
85.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANIX FAQ
What was Anixa Biosciences’s price range in the past 12 months?
Anixa Biosciences lowest stock price was $2.07 and its highest was $5.09 in the past 12 months.
What is Anixa Biosciences’s market cap?
Anixa Biosciences’s market cap is $83.07M.
When is Anixa Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anixa Biosciences’s earnings last quarter?
Anixa Biosciences released its earnings results on Mar 10, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.08.
Is Anixa Biosciences overvalued?
According to Wall Street analysts Anixa Biosciences’s price is currently Undervalued.
Does Anixa Biosciences pay dividends?
Anixa Biosciences does not currently pay dividends.
What is Anixa Biosciences’s EPS estimate?
Anixa Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anixa Biosciences have?
Anixa Biosciences has 32,196,860 shares outstanding.
What happened to Anixa Biosciences’s price movement after its last earnings report?
Anixa Biosciences reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -5.797%.
Which hedge fund is a major shareholder of Anixa Biosciences?
Currently, no hedge funds are holding shares in ANIX
---
Anixa Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (171.32% Upside)
$7.00 (171.32% Upside)
Insider Transactions
Bought Shares
Worth $115.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 25.1%
Last 30 Days ▲ 25.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.49%
12-Months-Change
Fundamentals
Return on Equity
-56.63%
Trailing 12-Months
Asset Growth
-15.40%
Trailing 12-Months
Company Description
Anixa Biosciences
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
---
ANIX Stock 12 Month Forecast
Average Price Target
$7.00
▲(171.32% Upside)
Technical Analysis
Best Analysts Covering ANIX
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-18.68%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -18.68% per trade.
---